ImpriMed Raises $10 Million to Advance AI-Driven Veterinary Precision Oncology

Precision-medicine company ImpriMed has secured a $10 million Series A2 bridge round, with NAVER D2SF participating, as the company expands its AI-driven drug-response platform and moves toward U.S. commercialization.

NAVER D2SF, the corporate venture arm of South Korea’s NAVER, announced its investment on September 18, 2026. The investment forms part of ImpriMed’s $10 million Series A2 bridge financing.

ImpriMed combines functional testing of patient-derived cancer cells with genomic, immunophenotypic and clinical information to support personalised cancer-treatment decisions.

The company has built its initial commercial and clinical experience in veterinary oncology, particularly canine and feline lymphoma.

From Veterinary Oncology to Precision Medicine

ImpriMed’s technology is based on a different approach from conventional diagnostic testing.

Instead of relying solely on tumour classification or genetic markers, the company evaluates how a patient’s living cancer cells respond to different drugs outside the body.

This functional information can then be combined with other patient data to generate treatment-response predictions.

The approach creates a potential workflow:

Patient → tumour/cancer cells → ex vivo drug testing → multimodal data → AI analysis → treatment-response prediction

The model is particularly relevant in cancers where multiple treatment options may exist but individual patients can respond differently to the same therapy.

More Than 27,000 Veterinary Lymphoma Tests

According to NAVER D2SF, ImpriMed has performed more than 27,000 tests involving canine and feline lymphoma to help guide treatment decisions.

The company says its veterinary solutions are currently used by more than 600 veterinary hospitals across the United States, Canada, the United Kingdom, France and South Korea.

This veterinary footprint is strategically important because it gives ImpriMed an existing clinical-use environment in which to develop and validate its precision-medicine approach.

NAVER D2SF also reported that a retrospective study associated ImpriMed’s approach with a threefold increase in survival time and a fourfold improvement in treatment response.

Those findings should be interpreted as reported study results rather than proof that AI-guided treatment improves outcomes across all lymphoma patients; retrospective evidence can be affected by patient selection, treatment differences and other confounding factors.

The AI Layer

ImpriMed’s platform combines several categories of information rather than treating AI as a standalone diagnostic tool.

The company integrates:

• functional drug-response data;

• genomic information;

• immunophenotypic characteristics;

• clinical information; and

• real-world treatment data.

According to the company’s recent financing announcement, its AI models are being trained using more than 3.5 million data points.

This creates a potentially valuable feedback loop:

More patients → more biological and treatment-response data → stronger models → broader clinical use → additional data

The quality, standardisation and clinical relevance of that data will therefore be central to the platform’s long-term value.

Why Veterinary Oncology Is Strategically Important

Veterinary oncology provides an interesting environment for precision medicine.

Dogs and cats naturally develop cancers with biological characteristics that can overlap with human cancers, while veterinary oncology also provides a comparatively concentrated specialist ecosystem.

For ImpriMed, veterinary medicine has functioned as an important commercial and clinical application area while the company expands into human precision medicine.

NAVER D2SF explicitly described ImpriMed’s veterinary experience as supporting its broader healthcare expansion.

The company’s South Korean operations are also moving into human medicine, including software for multiple myeloma prognosis and therapy-response prediction.

Regulatory and Commercial Expansion

ImpriMed is targeting U.S. regulatory and commercial milestones as it expands beyond its existing veterinary business.

NAVER D2SF said the company is pursuing FDA clearance and CLIA certification by the first quarter of 2027 for its human-health diagnostic expansion. The company is also expanding into Asia while building its U.S. commercial presence.

This creates two distinct but connected businesses:

Veterinary precision oncology – Existing clinical use → lymphoma testing → veterinary oncology network → real-world evidence

Human precision medicine – Functional cancer testing → AI prediction → regulatory clearance → hospital partnerships → commercial diagnostics

The veterinary business therefore represents more than a standalone animal-health application. It is part of the company’s broader precision-medicine development strategy.

$10 Million Financing — Key Facts

The Emerging Veterinary Oncology Value Chain

ImpriMed illustrates how veterinary oncology is becoming increasingly data-driven.

The traditional pathway has often been: Diagnosis → tumour classification → treatment protocol

The emerging precision-oncology model is more granular: Diagnosis → tumour biology → functional drug response → AI prediction → treatment selection → outcome data

This could shift the competitive landscape toward companies capable of combining diagnostics, biological testing, software and clinical data.

For veterinary practices, the potential value is not simply a new diagnostic result. It is the possibility of receiving actionable information about which therapies may be more likely to work for an individual patient.

Strategic Significance for Animal Health

The financing signals a broader convergence between three traditionally separate animal-health categories: Diagnostics + AI + therapeutics

Historically, these businesses have often developed independently. Precision oncology creates a different model in which:

• diagnostics generate biological data;

• functional testing generates treatment-response data;

• AI converts multiple data streams into predictions; and

• therapeutic decisions generate additional outcome data.

This creates a potentially compounding data asset.

For investors and animal-health companies, the important question is therefore not only how many tests a platform performs, but whether those tests create clinically useful, proprietary and repeatable treatment-response data.

What to Watch Next

The next phase of ImpriMed’s development will centre on several measurable milestones:

1. FDA regulatory progress for its human-health diagnostic products.

2. CLIA certification and U.S. laboratory expansion.

3. Expansion of the veterinary hospital network.

4. Additional prospective evidence supporting treatment-response predictions.

5. Demonstration that AI predictions translate into clinically meaningful outcomes.

6. Expansion from lymphoma into additional cancers.

7. Commercial adoption by veterinary oncologists and specialty hospitals.

8. Development of the company’s human-health business in Asia and North America.

Bottom Line

ImpriMed’s $10 million Series A2 bridge represents more than another AI-healthcare financing round.

Its distinctive feature is the company’s evolution from veterinary precision oncology toward a broader precision-medicine platform.

The reported 27,000-plus canine and feline lymphoma tests provide an established veterinary application base, while the company’s multimodal AI approach seeks to connect cancer biology with treatment selection.

The strategic model is increasingly clear: Diagnostics → functional tumour testing → AI → personalised drug selection → clinical outcomes

If regulatory and clinical milestones are achieved, this architecture could make veterinary oncology an important proving ground for a broader precision-medicine business.

For the animal-health industry, ImpriMed is a notable example of the sector’s transition from diagnosing disease to predicting treatment response.